Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB801 + docetaxel
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Small Molecules
- Administration
- Oral (AB801), Intravenous (docetaxel)
01
Overview
AB801 + docetaxel is an investigational combination therapy for cancer composed of **AB801**, a potent and highly selective small molecule inhibitor of the receptor tyrosine kinase **AXL**, and **docetaxel**, a taxane-class chemotherapeutic agent. AB801 targets and inhibits AXL signaling which mediates resistance to multiple therapies and fosters an immunosuppressive tumor microenvironment. Preclinical studies show that AB801 enhances sensitivity to chemotherapy, including docetaxel, by increasing DNA damage in cancer cells, overcoming AXL-mediated resistance, and improving anti-tumor responses[1][2][3][4][5][6][7][8]. The combination is currently being evaluated in clinical trials for advanced solid tumors, including non-small cell lung cancer (NSCLC) and other malignancies[9][5].
- Other names
- AB801 + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))AXL (AXL receptor tyrosine kinase)STK17A (Serine/threonine kinase 17a)
Beyond the preview
Go deeper on AB801 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB801 + docetaxel.